The latest price target for Lisata Therapeutics (NASDAQ:LSTA) was reported by HC Wainwright & Co. on November 21, 2024. The analyst firm set a price target for $15.00 expecting LSTA to rise to within 12 months (a possible 411.95% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Lisata Therapeutics (NASDAQ:LSTA) was provided by HC Wainwright & Co., and Lisata Therapeutics reiterated their buy rating.

There is no last upgrade for Lisata Therapeutics

There is no last downgrade for Lisata Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lisata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lisata Therapeutics was filed on November 21, 2024 so you should expect the next rating to be made available sometime around November 21, 2025.

While ratings are subjective and will change, the latest Lisata Therapeutics (LSTA) rating was a reiterated with a price target of $15.00 to $15.00. The current price Lisata Therapeutics (LSTA) is trading at is $2.93, which is out of the analyst’s predicted range.